Shooting yourself in the foot, pharma style
This article was originally published in Scrip
The removal of Chris Viehbacher from the helm of Sanofi last week was a big shock. The loss of more than €18bn from the company's market capitalization was an indication that nobody (outside the company's higher echelons at least) really expected such a dramatic event to occur. Even if there had been rumblings of discontent as indicated by the CEO's letter dated early September and leaked in late October, in which he questioned the board over their intentions for his position, still it felt unlikely that the axe would fall so suddenly and absolutely.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.